Biological Basis for Increased Risk of Graft Loss in African American (AA)-APOL1 and Beyond
|
|
|
- Asher Copeland
- 5 years ago
- Views:
Transcription
1 Biological Basis for Increased Risk of Graft Loss in African American (AA)-APOL1 and Beyond Jonah Odim, MBA, MD, PhD Chief, Clinical Transplantation Division of Allergy, Immunology, and Transplantation (DAIT) National Institute of Allergy and Infectious Disease (NIAID)/NIH
2 Disclosures: Speaker is on the APOLLO Steering Committee No financial conflicts of interest No other disclosures or conflicts Presentation does not discuss off label use of any therapeutics or diagnostics Views expressed are not from, or that of, DHHS, NIH, NIDDK, NIMHD, NIAID, DAIT, TB or the Federal government but represent views of the speaker
3 Learning Objectives 1) Through analysis of the biological basis for increased risk of kidney allograft loss in Americans of recent African ancestry (AA) and APOL-1 demonstrate an understanding of the biology and potential ethical, legal, social, and policy challenges that may accompany the translation of this new genomic knowledge into clinical transplantation and public health practice 2) Prospective Study of APOL1 in Kidney Transplantation: NIH-supported APOL-1 Long-term Kidney Transplantation Outcomes Network (APOLLO) national study to assess whether AA kidney donor APOL1 genotypes predict shorter allograft survival in recipients and the postdonation health in living AA donors
4 MYH9 is associated with nondiabetic end-stage-renal disease in African Americans Nature Genetics 40:10; African American Other Ethnic Americans Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans Science 2010: 329:5993;
5 Two high-risk variants in the APOL1 gene (G1 and G2) have increased high frequency in Africa because they confer protection from Trypanosoma brucei rhodesiense infection (sleeping sickness)
6 Opportunity for deeper understanding of disease mechanism (s) and personalized renal transplantation 2 high-risk renal alleles/variants (G1, G2) 0 or 1 high-risk allele/variant (G0)
7 The presence of 2 high risk renal variants in AA kidney provides the mechanistic tapestry for earlier progression to non-diabetic end stage renal disease in AA 2 high-risk renal alleles (G1, G2) vs. 0 or 1 high risk allele Deceased donor kidney transplantation Living donor kidney transplantation Biological mechanism NIH supported: APOL1 Long-term kidney transplantation outcomes network (APOLLO)
8 Kidneys from deceased AA donors with 2 APOL1 high risk alleles are associated with increased risk of allograft failure and reduced function Daniel (AJT) 2011 Freedman (AJT) 2015 Freedman (AJT) 2016 Transplant center WF WF, UNC, UAB WF, UNC, UAB Emory, DeKAF Transplant subjects (renal) or 1 high risk APOL1 variants 114 (84%) 576 (85%) 981 (85%) 2 high risk APOL1 variants 22 (16%) 99 (15%) 172 (15%) Follow-up (m) Adjust hazard ratio for allograft failure with 2 vs. 0/1 high risk variants 3.84 (no 95% CI) 2.26 (95% CI: ) 2.05 (95% CI: ) though most recipients of a donor graft with 2 APOL1 high-risk gene variants do not develop early allograft failure (? 2 nd hit)
9 The effect of adjusting the present KDRI equation by using APOL1 genotype instead of race adds more precision to the KAS
10 APOL1 and living donor outcomes Lower egfr with 2 APOL1 risk alleles Doshi et al JASN 2018 Post-Donation: Greater proportion have CKD 3 or lower
11 Direct evidence linking APOL1 gene to pathogenesis was challenging since this gene is only present in some primates and humans
12 Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Beckerman P: Nature Medicine (2017) 23:4; Generation of a mouse model with cell-type-specific inducible expression of APOL1 variants Evidence APOL1 variants cause kidney disease not simply disease association
13
14 APOL1 and kidney transplantation 2 vs. (0-1)APOL1 high-risk renal variants in donor 1 Increased risk of graft failure in the recipient 2 Recipient APOL1 alleles no impact on graft outcomes (donor genotype drives outcome phenotype) 3 BUT, 4 5 subjects with high-risk kidney variants do not develop early graft failure (? requires 2 nd trigger or hit) 4 Increased risk of CKD in AA living donors
15 Quo vadis mandatory APOL1 genetic testing? APOL1 Long-term kidney transplantation outcomes network ( prospectively assess whether AA kidney donor high-risk renal APOL1 variants predict shorter allograft survival in recipients and post-donation health in living donors
16 Acknowledgements Patients and human research subjects Wake Forest Scientific and Data Research Center APOLLO Network Investigators United Network Organ Sharing (UNOS) Scientific Registry of Transplant Recipients (SRTR) Association of Organ Procurement Organizations (AOPO) American Society of Histocompatibility and Immunogenetics (ASHI) Cutting Edge of Transplantation (CEOT) QUESTIONS?
Hasan Fattah 3/19/2013
Hasan Fattah 3/19/2013 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels
Chronic kidney disease in African Americans: Puzzle pieces are falling into place
ADDRESSING DISPARITIES IN HEALTHCARE LEARNING OBJECTIVE: Readers will recognize recent advances in the understanding of chronic kidney disease in African Americans JOSEPH V. NALLY, JR, MD Former Director,
Are two better than one?
Are two better than one? Disclosures Ryutaro Hirose, MD Professor in Clinical Surgery University of California, San Francisco I have no relevant disclosures related to this presentation The PROBLEM There
Anna Vinnikova, MD APOL1
Anna Vinnikova, MD APOL1 I have no relevant financial relationships with commercial interests But I have a passionate interest in the following problem: National decline in Nephrology Fellowship applications
Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes.
Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes. Casey R. Dorr, Minneapolis Medical Research Foundation Barry I. Freedman, Wake Forest University
DIVISION OF NEPHROLOGY
The Division s funding from the NIH has increased from $3.7 Million in 2001 to over $11 Million in 2006. DIVISION OF NEPHROLOGY DR. BARBARA MURPHY was voted President-Elect of the American Society of Transplantation
New Ways to Tackle a Growing Health Care Dilemma - ESRD
New Ways to Tackle a Growing Health Care Dilemma - ESRD J. Keith Melancon, M.D., F.A.C.S. George Washington University Professor of Surgery Chief, Transplant Surgery and Transplant Institute Thanks to
The New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
Long-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota
Long-term Non-ESRD Kidney Donor Risks Arthur Matas Dept Surgery University of Minnesota Conflict of Interest Disclosure I have no relevant financial relationships to disclose No off label use will be discussed
The Kidney Allocation System Changed in a Substantive Way on December 5, Your Patients Have Been, and Will Be, Affected by These Changes
The Kidney Allocation System Changed in a Substantive Way on December 5, 2014 Your Patients Have Been, and Will Be, Affected by These Changes 1 The New Kidney Allocation System Terms of Importance Pediatric
HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01.
Kidney transplant results in children: progress made, but blacks lag behind Vikas R. Dharnidharka, MD, MPH 1 and Michael E. Seifert, MD 1,2 1 Division of Pediatric Nephrology, Washington University School
Scores in kidney transplantation: How can we use them?
Scores in kidney transplantation: How can we use them? Actualités Néphrologiques 2017 M Hazzan (Lille France ) Contents Scores to estimate the quality of the graft Scores to estimate old candidates to
Interventions in the Deceased Organ Donor to Improve Organ Quality and Quantity
Interventions in the Deceased Organ Donor to Improve Organ Quality and Quantity Sandy Feng, MD PhD Professor of Surgery University of California San Francisco Conflict of Interest Disclosure I have no
Update on Kidney Allocation
Update on Kidney Allocation 23rd Annual Conference Association for Multicultural Affairs in Transplantation Silas P. Norman, M.D., M.P.H. Associate Professor Division of Nephrology September 23, 2015 Disclosures
Innovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
Karnofsky Performance Score and Its Use in Risk Adjustment of Transplant Outcomes in the United States
Karnofsky Performance Score and Its Use in Risk Adjustment of Transplant Outcomes in the United States Jon J Snyder, PhD* Nicholas J Salkowski, PhD Kenneth E Lamb, PhD David A Zaun, MS Taqee A Khaled,
Transplant Update New Kidney Allocation System Transplant Referral Strategies. Antonia Harford, MD University of New Mexico
Transplant Update New Kidney Allocation System Transplant Referral Strategies Antonia Harford, MD University of New Mexico Financial Disclosures Doctor Harford has received financial support for dialysis
Understanding Pharmaceutical Care Needs of Living Kidney Donors through Linked Transplant Registry and Pharmacy Claims Data
Understanding Pharmaceutical Care Needs of Living Kidney Donors through Linked Transplant Registry and Pharmacy Claims Data The SRTR Living Donor Collective Lentine KL, 1 Gustafson SK, 2 Schnitzler MA,
Literature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
Developing a Kidney Waiting List Calculator
Developing a Kidney Waiting List Calculator Jon J. Snyder, PhD* Nicholas Salkowski, PhD, Jiannong Liu, PhD, Kenneth Lamb, PhD, Bryn Thompson, MPH, Ajay Israni, MD, MS, and Bertram Kasiske, MD, FACP *Presenter
U.S. changes in Kidney Allocation
U.S. changes in Kidney Allocation Match kidneys with longest survival to patients with longest survival No parallel matching for kidneys with lower survival potential Decrease discard of kidneys with lower
UEMS & EBS: DIVISION OF TRANSPLANT SURGERY
CURRICULUM AND SYLLABUS TRANSPLANTATION Module 1: Multi-organ retrieval Ability to evaluate donor suitability Ability to retrieve abdominal organs for transplantation Evaluation of donor/ organs suitability
FAIRNESS/EQUITY UTILITY/EFFICACY EFFICIENCY. The new kidney allocation system (KAS) what has it done? 9/26/2018. Disclosures
The new kidney allocation system (KAS) what has it done? Disclosures No financial disclosure Ryutaro Hirose, MD Professor in Clinical Surgery University of California San Francisco Objectives Describe
Thanks to our Speakers!
Thanks to our Speakers! Fizza Naqvi, MD Assistant Professor at the Department of Medicine (Nephrology), Johns Hopkins Attending physician at Johns Hopkins hospital. Involved with kidney recipient evaluation
Pediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
OPTN/SRTR 2016 Annual Data Report: Preface
OPTN/SRTR 2016 Annual Data Report: Preface This Annual Data Report of the US Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR) is the twenty-sixth
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
Simultaneous Pancreas Kidney Transplantation:
Simultaneous Pancreas Kidney Transplantation: What is the added advantage, and for whom? Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney
Association Analysis of the Reticulon 1 Gene in End-Stage Kidney Disease
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Received: August 26, 2015 Accepted: September 16, 2015 Published online: October 24, 2015 Association Analysis of
SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
User Guide. A. Program Summary B. Waiting List Information C. Transplant Information
User Guide This report contains a wide range of useful information about the kidney transplant program at (FLMR). The report has three main sections: A. Program Summary B. Waiting List Information The
Indian Journal of Nephrology Indian J Nephrol 2001;11: 88-97
88 Indian Journal of Nephrology Indian J Nephrol 2001;11: 88-97 ARTICLE HLA gene and haplotype frequency in renal transplant recipients and donors of Uttar Pradesh (North India) S Agrawal, AK Singh, RK
LIVE KIDNEY DONOR RISK PREDICTION ; NEW PARADIGM, NEW CALCULATORS PEDRAM AHMADPOOR MD
LIVE KIDNEY DONOR RISK PREDICTION ; NEW PARADIGM, NEW CALCULATORS PEDRAM AHMADPOOR MD Outline: PART 1 : Update on safety of nephrectomy for living donor candidate PART 2 : Latest guideline recommendation
Organ Donation. United States and European Union Perspective
Organ Donation United States and European Union Perspective Carina Sokalski - Gonzalo Perez SANIT- December 14, 2004 Two Types of Organ Donation Deceased Organ Donation The majority of organ donors are
Living Kidney Donation. Dr. Joseph Keith Melancon
Living Kidney Donation Dr. Joseph Keith Melancon Thanks to our speaker! Keith Melancon, MD Chief Transplant Institute And Division Of Transplant Surgery; Medical Director GW/ Ron And Joy Paul Kidney Center
Answers to Your Questions about a Change in Kidney Allocation Policy What you need to know
Answers to Your Questions about a Change in Kidney Allocation Policy What you need to know Who are UNOS and the OPTN? The United Network for Organ Sharing (UNOS) is a nonprofit organization that operates
living donor kidney transplantation pdf Living Kidney Donor Information » National Kidney Federation
DOWNLOAD OR READ : LIVING DONOR KIDNEY TRANSPLANTATION CURRENT PRACTICES EMERGING TRENDS AND EVOLVING CHALLENGESLIVING DOWNSTREAM AN ECOLOGISTS PERSONAL INVESTIGATION OF CANCER AND THE ENVIRONMENT PDF
Transplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
Transplant Program Performance Measures Review Outcome Measures Work Group Update. Membership and Professional Standards Committee December 2015
Transplant Program Performance Measures Review Outcome Measures Work Group Update Membership and Professional Standards Committee December 2015 Collaboration MPSC Work Group David Cronin, Chair David Axelrod
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation Titte R Srinivas, MD, FAST Medical Director, Kidney and Pancreas Transplant Programs Objectives: Describe trends
Acute kidney injury after transplantation = Delayed graft function (DGF)
Acute kidney injury after transplantation = Delayed graft function (DGF) PD Dr. med. Bernd Schröppel Section of Nephrology University Hospital Ulm, Germany 1 DGF and donor source Live donor: 3% Standard
The Future What Would an Ideal Report Card Look Like. Jesse Schold, PhD Cleveland Clinic Cleveland, Ohio
The Future What Would an Ideal Report Card Look Like Jesse Schold, PhD Cleveland Clinic Cleveland, Ohio Disclosure No disclosures to report related to the content of this presentation Audience Poll Question
Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
Chapter 7. Australian Waiting List. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter 7 Australian Waiting List 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Stock and Flow The waiting list data reported here are derived from the Australian National Organ Matching System
Donation from Old Living Donors How safe is it? Safe for recipient or donor?
Donation from Old Living Donors How safe is it? Safe for recipient or donor? Pr Lionel Rostaing Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation CHU Grenoble Alpes France lrostaing@chu-grenoble.fr
Questions and Answers for Transplant Candidates about the Kidney Allocation System
TA L K I N G A B O U T T R A N S P L A N TAT I O N Questions and Answers for Transplant Candidates about the Kidney Allocation System United Network for Organ Sharing (UNOS) is a non-profit charitable
Clinical Questions of Combined Liver Kidney Transplantation
Clinical Questions of Combined Liver Kidney Transplantation Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Methodist University Hospital, Transplant Institute Division of Transplantation,
Histocompatibility antigens
Histocompatibility antigens Tuesday 09 November 2010 Telegraph UK Livers grown in the laboratory could eventually solve organ transplant shortage. Made-to-measure organs for transplantation are a step
Should red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
A POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION
THE NEW KIDNEY ALLOCATION SYSTEM: A POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION Paul Warner, PhD, D(ABHI) Director, HLA/Immunogenetics Laboratory Bloodworks Northwest Seattle, Washington Disclosure
Donor Quality Assessment
Donor Quality Assessment Francesc Moreso, MD, PhD Renal Transplant Unit Hospital Universitari Vall d Hebron Barcelona. Spain 4/9/2017 Donor Quality Assessment 1 What is the problem? Across all age ranges,
Kidney Transplant in the Elderly. Robert Santella, M.D., F.A.C.P.
Kidney Transplant in the Elderly! Robert Santella, M.D., F.A.C.P. Incident Rate of ESRD by Age Age 75+ 65-74 From US Renal Data System, 2012 Should there be an age limit? Various guidelines: Canadian,
Outcomes of Adult Dual Kidney Transplants by KDRI in the United States
American Journal of Transplantation 2013; 13: 2433 2440 Wiley Periodicals Inc. Brief Communication C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons
Transplant and Dialysis Information
Transplant and Dialysis Information Dialysis and Transplant Information This document is intended to be an easy-to-read guide to help patients, families and friends understand the options when addressing
Marginal donors: Young vs. Old
Marginal donors: Young vs. Old Why we should prefer older donors Geir Mjøen, Oslo, Norway Long term risks in kidney donors Interpretation Consequences Recommendation Kidney donors Donors are healthy at
Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
A Guide to Better Living
Transplantation What Is a Kidney Transplant? Kidney transplantation is placing a kidney from one person (donor) into a patient with kidney failure (recipient). This is done by surgery where the donated
Case # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
Waiting for a Kidney. Objectives
Waiting for a Kidney Department of Urologic Sciences Grand Rounds William Gourlay Christopher Nguan April 25, 2007 Objectives 1. review the waiting times for deceased-donor kidney transplants in BC and
Report on the Transplantation Transmission Sentinel Network (TTSN)
Report on the Transplantation Transmission Sentinel Network (TTSN) CATB Session - AATB s 31st Annual Meeting, Boston September 15, 2007 Scott Brubaker, CTBS AATB Representative, TTSN Advisory Group TTSN
HBV, HCV, HIV and Kidney Transplantation. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
HBV, HCV, HIV and Kidney Transplantation Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Objectives Prevalence of hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency
Embracing the Magic: Increasing Organ Acceptance Rates Through Data Review and Risk Stratification
Embracing the Magic: Increasing Organ Acceptance Rates Through Data Review and Risk Stratification Presented by: Sandy Felty, RN, MSN, MHA Lynette Martin del Campo, RN, MSN, FNP-C Sharon Norfles, RN, BSN
2017 UNOS Liver Distribution Proposal Discussion: David Goldberg
2017 UNOS Liver Distribution Proposal Discussion: David Goldberg Who am I? Transplant hepatologist at the University of Pennsylvania Medical Director of Living Donor Liver Transplant NIH-funded epidemiologist
Addressing Healthcare Disparities in Autoimmune Disease: A Focus On Systemic Lupus Erythematosus in the USA
Addressing Healthcare Disparities in Autoimmune Disease: A Focus On Systemic Lupus Erythematosus in the USA by Halima Moncrieffe, PhD halima.moncrieffe@cchmc.org Center for Autoimmune Genomics & Etiology,
Pancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK
The MHC and Transplantation Brendan Clark Transplant Immunology, St James s University Hospital, Leeds, UK Blood Groups Immunofluorescent staining has revealed blood group substance in the cell membranes
Using GIS for Analyzing Optimal Organ Allocation for Liver Transplantation
Using GIS for Analyzing Optimal Organ Allocation for Liver Transplantation September 7, 2011 1 Presenters: Naoru Koizumi 1, Amit Patel 1,Yang Xu 1, Nigel Waters 1, Monica Gentili 2, Ammar Malik 1, Dennis
Literature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
Does Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality donor kidneys?
Nephrol Dial Transplant (2017) 32: 1934 1938 doi: 10.1093/ndt/gfx257 Advance Access publication 21 August 2017 Does Kidney Donor Risk Index implementation lead to the transplantation of more and higher-quality
Annual Statistics on Organ Replacement in Canada
CIHI Snapshot December 2017 Annual Statistics on Organ Replacement in Canada Dialysis, Transplantation and Donation, 2007 to 2016 This summary document provides key findings from the latest annual statistics
Organ transplantation in Bulgaria
Cell Tissue Banking (28) 9:337 342 DOI 1.17/s1561-7-935-2 Organ transplantation in Bulgaria Elissaveta Naumova Æ Petar Panchev Æ Pencho J. Simeonov Æ Anastassia Mihaylova Æ Kalina Penkova Æ Petia Boneva
Organ Transplantation Program Update
Organ Transplantation Program Update March 7, 2013 Christopher J. McLaughlin Chief, Organ Transplantation Branch Division of Transplantation Department of Health and Human Services Health Resources and
Renal Transplant Past Present and Future David Landsberg
2012 Renal Transplant Past Present and Future David Landsberg Outline Changing pattern of Donors Types of Donors Allocation Results Challenges in the Elderly LDPE Transplants By Year LD LRD LUD NDAD DD
The Organ and Tissue Donor Program
The Organ and Tissue Donor Program If I needed a kidney or some other vital organ to live Would I be able to get one? Maybe. Many people who need organ transplants cannot get them because of a shortage
Older Living Kidney Donors and Recipients. Charles Le University of Colorado 6/24/11
Older Living Kidney Donors and Recipients Charles Le University of Colorado 6/24/11 Clinical Scenario HPI: 60 y/o healthy AAM with h/o CKD5 on HD x 2 yrs 2/2 HTN, was evaluated in transplant clinic for
Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act. Safeguards and Research Criteria for Transplantation of Organs Infected with
This document is scheduled to be published in the Federal Register on 11/25/2015 and available online at http://federalregister.gov/a/2015-30172, and on FDsys.gov [Billing Code 4140-01-P] DEPARTMENT OF
Consultation document on Organ Donation and Transplantation Response Form
Consultation document on Organ Donation and Transplantation Response Form Contact details of person and/or institution submitting comments Name of person Address e-mail address Knud Erben erben@ceapir.org
Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB
Public Comment Proposal Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB OPTN/UNOS Operations and Safety Committee Prepared by: Susan Tlusty UNOS Policy Department Contents Executive Summary
The NJ Sharing Network Organ and Tissue Donation as an End of Life option for Families
The NJ Sharing Network Organ and Tissue Donation as an End of Life option for Families NJ Sharing Network Private non-profit service organization Federal designation to provide recovery services State
The Value of Community- Based Initiatives
The Value of Community- Based Initiatives Saving Lives Through Blood and Marrow transplantation Jeffrey Chell, MD 1 What is Bone Marrow? The blood-forming cells in the hollow portion of our bones Looks
APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair.
APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Tomek Kofman, Vincent Audard, Céline Narjoz, Olivier Gribouval, Marie Matignon, Claire Leibler, Dominique Desvaux,
The National Kidney Foundation (NKF) is pleased to submit testimony regarding the impact of
STATEMENT OF THE NATIONAL KIDNEY FOUNDATION 30 EAST 33 RD STREET NEW YORK, NY 10016 SUBMITTED TO THE HOUSE COMMITTEE ON APPROPRIATIONS; SUBCOMMITTEE ON LABOR, HHS, EDUCATION, AND RELATED AGENCIES IN SUPPORT
Update on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
End Stage Kidney Disease Among Indigenous Peoples of Australia and New Zealand
Chapter 12 End Stage Kidney Disease Among Indigenous Peoples of and New Zealand 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, rates of end-stage kidney disease
New Treatments for ADPKD how close are we?
New Treatments for ADPKD how close are we? Leicester General Hospital 28 Jan 2012 Professor Albert Ong a.ong@sheffield.ac.uk The cystic degeneration of the kidneys, once it reaches the point where it can
Disclosures. Normothermic Machine Liver Perfusion
Disclosures Normothermic Machine Liver Perfusion I have nothing to disclose Garrett R. Roll, MD Assistant Professor of Surgery Overview Define normothermic machine liver perfusion (NMLP) Show device examples
Case 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
Progress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
Management of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
Welcome to. The Fundamentals of International Clinical Research Workshop. Stevenson, Washington
Welcome to The Fundamentals of International Stevenson, Washington Robin M. Mason, MS, MBA Division of Microbiology and Infectious Diseases of Allergy and Infectious Diseases NIH, DHHS Fundamentals of
Shipping living donor kidneys and transplant recipient outcomes
Received: 8 June 2017 Revised: 20 October 2017 Accepted: 13 November 2017 DOI: 10.1111/ajt.14597 ORIGINAL ARTICLE Shipping living donor kidneys and transplant recipient outcomes Eric Treat 1 Eric K. H.
NHSBT Board July Update on UK Living Kidney Sharing Scheme
1. Status Public 2. Executive Summary NHSBT Board July 27 2017 Update on UK Living Kidney Sharing Scheme This paper provides an update on activity and plans for the UK Living Kidney Sharing Scheme (UKLKSS),
STATEMENT OF THE NATIONAL KIDNEY FOUNDATION SUBMITTED TO THE HOUSE COMMITTEE ON APPROPRIATIONS;
STATEMENT OF THE NATIONAL KIDNEY FOUNDATION 30 EAST 33 RD STREET NEW YORK, NY 10016 SUBMITTED TO THE HOUSE COMMITTEE ON APPROPRIATIONS; SUBCOMMITTEE ON LABOR, HHS, EDUCATION, AND RELATED AGENCIES March
DCD Heart Donation Understanding the Regulatory, Ethical and Clinical Issues. Valluvan Jeevanandam MD University of Chicago Medicine
DCD Heart Donation Understanding the Regulatory, Ethical and Clinical Issues Valluvan Jeevanandam MD University of Chicago Medicine Disclosure Txn None MCS Scientific Advisor Thoratec/Abbott: Chairman
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE
Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE Best Therapy for Kidney Re- Transplantation? PREVENTION!!!! Registries CTS OPTN UNOS USRDS SRTR
Current strategies to kidney allocation
Current strategies to kidney allocation Dr Marie Alice Macher Dr Christian Jacquelinet Emilie Savoye Dr Corinne Antoine Direction Prélèvement Greffe organes - tissus From organ sharing to organ allocation
Disparities in Transplantation Caution: Life is not fair.
Disparities in Transplantation Caution: Life is not fair. Tuesday October 30 th 2018 Caroline Rochon, MD, FACS Surgical Director, Kidney Transplant Program Hartford Hospital, Connecticut Outline Differences
Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
Blood Types and Genetics
Blood Types and Genetics Human blood type is determined by codominant alleles. An allele is one of several different forms of genetic information that is present in our DNA at a specific location on a